SEC Opens Investigation into Boeing Co. over Safety Statements 
Coca-Cola Named New President of Its Namesake Foundation 
OpenAI Set to Unveil Google Rival Search Tool Next Monday, Sources Reveal 
Kith and ASICS Gear Up for an Exclusive Sneaker Launch Inspired by South Korea 
How is China being taught at Australian universities? 
Eating Sustainably in Development Project Managed by Alexander v Berenstain 
Heat is coming for our crops. We have to make them ready 
USAID and The Coca-Cola Foundation Launch Initiative to Combat Plastic Waste in Nigeria 
Novavax, Sanofi Ink Deal to Commercialize COVID-19 Vaccine to Jointly Produce Combination Shots 
New faith schools in England could soon allocate all their places on religious grounds 
Honda Motor Posts 6-Fold Increase in 4Q Operating Profit of $1.96 Billion 
McDonald’s Sets Up Digital Marketing Fund to Introduce New Ordering Channels, Loyalty Program 
Sriracha Shortage Predicted as Huy Fong Foods Stops Production of Famous Chili Sauce 
Burger King Announces Grand Whopper Giveaway for Mother’s Day; Free Items Until June 
Ripple Partner SBI Holdings to Form Joint Venture in Japan with Chiliz for Sports Tokens 
Elon Musk Teases Revolutionary Full Self-Driving V12.4, Cybertruck to Wait 
BALTIMORE, April 05, 2016 -- WellDoc, a digital health technology leader, announced today that healthcare industry veteran Nick Harsh has joined the company as Vice President, Market Access. In this new role, Mr. Harsh will be responsible for leading WellDoc’s payer strategy, relationships and execution.
“WellDoc is utilizing 21st century technology to partner patients and their caregivers with medical providers to deliver better healthcare outcomes,” said Mr. Harsh. “I’m excited about my new role with WellDoc, and the impact we can make on the management of type 2 diabetes and other chronic diseases.”
Over the last 15 years, Mr. Harsh been a part of the management team for the AstraZeneca organization, launching and supporting several AstraZeneca and MedImmune well-recognized brands, including Nexium®, Crestor® and FluMist ®. Most recently, he led the commercial strategy, pricing, operations, and channel distribution services for MedImmune’s specialty biologics. Mr. Harsh has spent more than 30 years in the pharmaceutical, medical device and biotech fields—in senior commercial roles leading the market access initiatives.
“Nick is a great addition to our growing WellDoc leadership team,” said Kevin McRaith, Chief Executive Officer at WellDoc. “The breadth and depth of his managed market knowledge and experience with product commercialization will allow WellDoc to expand the market presence of BlueStar® and future digital health products.”
About WellDoc®
WellDoc is a digital health technology company that develops mobile solutions to drive behavioral and clinical change in chronic disease. WellDoc’s goal is to improve patient self-management and help physicians overcome gaps in the delivery system to improve clinical outcomes and decrease cost. WellDoc has commercialized BlueStar®, a digital therapeutic, for adults with type 2 diabetes. This therapeutic is designed to fill the support gap between patients and providers during the 8700 hours that individuals live their lives outside the healthcare system each year. WellDoc has a proven track record of contributing published, peer-reviewed clinical evidence since 2008 and in June 2015 presented real-world patient engagement and clinical outcomes at the American Diabetes Association’s (ADA) 75th Scientific Session. BlueStar® is recognized by the ADA on its website as the first and only in the new class of diabetes treatment known as Mobile Prescription Therapy. In a recently published Forbes blog, WellDoc was named among one of five healthcare tech companies to watch in 2016. For more information, visit www.WellDoc.com and www.BlueStarDiabetes.com.
Media contact: Juliette Bogus PressComm PR Tel: +410-980-5687 Email: [email protected]
